Trial Profile

A Phase I,Multicenter,Open-label,Single-arm Study:A Dose-escalation Phase Evaluating FS1502 in Patients With HER2 Expressed Advanced Solid Tumors,and a Dose-expanded Phase in Patients With Local Advanced or Metastatic,HER2+ Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Caxmotabart Entudotin (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Shanghai Fosun Pharmaceutical

12 Mar 2024 Planned primary completion date changed from 1 Sep 2023 to 30 Apr 2024.
12 Mar 2024 Status changed from recruiting to active, no longer recruiting.
06 Jun 2023 Results (n=70) assessing efficacy and safety of HER2-positive breast cancer (BC) pts treated with FS-1502 at the RP2D presented at the 59th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com